Skip to content

Instruments for Delirium Assessment Regarding to Analgesia Sedation and Ventilator Status

Instruments for Delirium Assessment Regarding to Analgesia Sedation and Ventilator Status

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01720914
Acronym
IDEAS
Enrollment
160
Registered
2012-11-02
Start date
2012-11-30
Completion date
2015-12-31
Last updated
2015-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium

Brief summary

In this prospective, multicenter observational study we assess the diagnostic validity of the following standard screening instruments for delirium regarding sedation, analgesia and ventilator status in critically ill patients: * Confusion Assessment Method for the ICU (CAM-ICU) * Intensive Care Delirium Screening Checklist (ICDSC) * Nursing-Delirium-Screening-Scale (Nu-DESC) The definite delirium diagnosis (definite in terms of reference standard) is made according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders 4th Edition, text revised (DSM-IV-TR) published by the American Psychiatric Association (APA) which is the Gold Standard to diagnose delirium. Primary research question: Does sedation, ventilator status and analgesia influence the sensitivity of delirium screening tools (DST)?

Interventions

None listed

Sponsors

Charite University, Berlin, Germany
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Critically ill patient * Patient age \> 18 years

Exclusion criteria

* Neurosurgical patients * Severe brain injury, intracerebral bleeding, stroke * Inability to communicate due to anacusia or severe hearing loss * Insufficient language comprehension * Patients \< 24 h total time of Intensive Care Unit stay * Deep sedation (RASS \< -3) for ≥ 7 days during study participation

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity of the delirium screening/diagnosing tool Confusion Assessment Method for the ICU (CAM-ICU) regarding sedation and ventilator status.Participants will be followed in the 7-days sample periodUsed reference standard: DSM-IV TR criteria
Sensitivity of the delirium-screening tool Intensive-Care Delirium Screening Checklist(ICDSC) regarding sedation and ventilator status.Participants will be followed in the 7-days sample periodUsed reference standard: DSM-IV TR criteria.
Sensitivity of the delirium screening tool Nursing Delirium Screening Scale (Nu-DESC) regarding sedation and ventilator status.Participants will be followed in the 7-days sample periodUsed reference standard: DSM-IV TR criteria

Secondary

MeasureTime frameDescription
Administered sedatives, cumulativeParticipants will be followed in the 7-days sample period
Specificity of the Confusion Assessment Method for the ICU (CAM-ICU), the Intensive Care Delirium Screening Checklist (ICDSC) and the Nursing Delirium Screening Scale regarding sedation and ventilator status.Participants will be followed in the 7-days sample periodUsed reference standard: DSM-IV-TR criteria.
Calculation and Analysis of the positive predictive values of the assessed delirium-screening scales.Participants will be followed in the 7-days sample periodCalculation of positive and negative predictive values of the Confusion Assessment Method for the ICU (CAM-ICU), the Intensive Care Delirium Screening Checklist (ICDSC) and the Nursing Delirium Screening Scale regarding sedation and ventilator status. Used reference standard: DSM-IV-TR criteria
Incidence of deliriumParticipants will be followed in the 7-days sample periodAccording to Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) and Confusion Assessment Method for the ICU (CAM-ICU)
Incidence of Subsyndromale Delirium (SSD)Participants will be followed in the 7-days sample periodAccording to Intensive Care Delirium Screening Checklist (ICDSC) and Nursing Delirium Screening Scale (Nu-DESC)
AnalgesiaParticipants will be followed in the 7-days sample period:According to Numeric rating scale visually enlarged and laminated (NRS-V), Behavioural pain scale (BPS) and Behavioural pain scale not intubated (BPS-NI)
Severity of illnessParticipants will be followed in the 7-days sample periodaccording to Acute Physiology And Chronic Health score (APACHE 2), Simplified Acute Physiology Score (SAPS 2) and Sequential Organ Failure Assessment score (SOFA)
Ventilator statusParticipants will be followed in the 7-days sample periodClinical observation of A) whether an airway is used B)whether a patient is ventilated with a positive pressure ventilation or a high flow ventilation for more than 6 hours per day.
ICU length of stayParticipants will be followed for the duration of intensive care unit stay and hospital stay, an expected average of 4 weeks
Duration of mechanical ventilationParticipants will be followed for the duration of intensive care unit stay and hospital stay, an expected average of 4 weeks
Discharge modeParticipants will be followed for the duration of intensive care unit stay and hospital stay, an expected average of 4 weeks
28-day mortalityParticipants will be followed for the duration of intensive care unit stay and hospital stay, an expected average of 4 weeks
Specificity of the Confusion Assessment Method for the ICU (CAM-ICU), the Intensive Care Delirium Screening Checklist (ICDSC) and the Nursing Delirium Screening Scale regarding analgesia.Participants will be followed in the 7-days sample periodUsed reference standard: DSM-IV-TR criteria.
Sensitivity of the Confusion Assessment Method for the ICU (CAM-ICU), the Intensive Care Delirium Screening Checklist (ICDSC) and the Nursing Delirium Screening Scale regarding analgesia.Participants will be followed in the 7-days sample periodUsed reference standard: DSM-IV-TR criteria.
Antibiotics/infectionsParticipants will be followed in the 7-days sample period
Administered neuroleptics, cumulativeParticipants will be followed in the 7-days sample period
Administered analgesics, cumulativeParticipants will be followed in the 7-days sample period

Countries

Brazil, Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026